Elutia (NASDAQ:ELUT) executives said the company sharpened its focus on drug-eluting biomatrix products during the first quarter of 2026, highlighting progress on its NXT-41 and NXT-41x regulatory programs, the launch of an automated manufacturing platform and ongoing strategic reviews of noncore product lines.
President and CEO Randy Mills said the company is increasingly positioning itself as a “pure-play drug-eluting biomatrix company” focused on breast reconstruction, which management described as a large market with significant unmet clinical need. Mills said Elutia continues to anticipate NXT-41 clearance in the fourth quarter of 2026 and NXT-41x clearance in the first half of 2027.
Company Emphasizes Breast Reconstruction Opportunity
Mills said Elutia sees a $1.5 billion U.S. market opportunity in breast reconstruction, citing approximately 168,000 breast reconstruction procedures performed in the United States last year and biologic mesh use in more than 85% of implant-based reconstructions. He said biologics account for roughly 65% of total procedural spending, with human biologic mesh selling for approximately $7,500 to $9,500 per breast.
Management framed NXT-41x as a potential improvement over legacy biologic matrices by combining a biologic matrix with sustained local antibiotic delivery. Mills said postoperative infection remains a significant issue in breast reconstruction, citing infection rates of 15% to 20%, serious complications in one in three women and implant loss rates of up to 21%. He also said the average hospital cost of a single infection is more than $48,000.
“This is not a market we have to create,” Mills said. “Biologic matrices are already deeply embedded into the standard of care.”
Mills also pointed to Elutia’s prior experience with EluPro, the company’s first-generation antibiotic-eluting bioenvelope, which was sold to Boston Scientific for $88 million in October. He said that experience supports management’s confidence in Elutia’s ability to develop, manufacture and commercialize drug-eluting products.
Automated Manufacturing Platform Comes Online
Elutia said it installed and operationalized core automated production equipment during the quarter to support NXT-41x manufacturing at scale. Mills said the robotic coating system is intended to enable precise and reproducible application of the drug-eluting layer onto the biologic matrix.
The company said the integrated manufacturing approach is designed to support scalability, efficiency and quality control. Mills said the platform supports a targeted gross margin of more than 80% at scale, which he said could allow NXT-41x to compete on both outcomes and cost.
Commercial readiness work is also underway. Mills said Chief Commercial Officer Pete Ligotti has been engaging directly with surgeons and hospital stakeholders. According to Mills, that work has reinforced management’s view that the clinical need is significant and that there has been limited innovation in the category.
Management also highlighted the concentrated nature of the market. Mills said about 1,800 U.S. hospitals perform breast reconstruction, but 585 hospitals account for three-quarters of the market, while the top 50 centers represent more than $300 million in spending. In response to an analyst question, Mills said the company expects to provide more detail on its launch structure on a future call.
First-Quarter Revenue Rises Slightly
CFO Matt Ferguson said first-quarter net sales from continuing operations were $3.1 million, compared with $3.0 million in the prior-year period, representing approximately 6% year-over-year growth. Continuing operations exclude the BioEnvelope business sold to Boston Scientific.
- SimpliDerm revenue was $2.1 million, compared with $2.6 million a year earlier.
- Cardiovascular revenue was $1.0 million, compared with $300,000 in the prior-year period.
- GAAP gross margin was 58%, compared with 47% a year earlier.
- Adjusted gross margin, excluding amortization of acquired intangible assets, was 67%, compared with 56%.
Ferguson said the increase in cardiovascular revenue was primarily driven by Elutia’s return to direct distribution and improved procedural volume. He said the year-over-year gross margin improvement reflected favorable product mix and price improvements.
Total operating expenses were $8.2 million, essentially flat from the prior-year period. Ferguson said litigation costs declined by about $2 million as the company worked through legacy matters, and that capacity was redeployed toward research and development progress and commercial readiness for NXT-41x.
Net loss was $7.5 million, compared with a net loss of $3.9 million a year earlier. Adjusted EBITDA was a loss of $4.4 million, compared with a loss of $2.8 million in the prior-year period. Ferguson said the increased net loss was driven primarily by non-cash items and other expense, specifically the revaluation of warrant liabilities, rather than deterioration in the underlying operating business.
Strategic Review Continues
Elutia ended the quarter with $28.5 million in cash on hand, plus $8 million in escrow tied to the BioEnvelope divestiture, which Ferguson said the company expects to be released in the fourth quarter of 2026. Combined, the company reported $36.5 million in cash and escrowed receivables.
Mills said Elutia remains engaged in two strategic processes: the previously announced evaluation of a SimpliDerm divestiture and newly disclosed inbound acquisition interest in its cardiovascular product line. He said SimpliDerm generated $2.1 million in quarterly revenue at a 57% gross margin, while the cardiovascular product line generated $1.0 million in revenue at an 85% gross margin.
During the question-and-answer portion of the call, Mills said interest in SimpliDerm has been “very robust,” with 38 targets engaged in the process. He said the company has “pretty good confidence” that a transaction is coming together but declined to provide a specific timeline. Mills also said Elutia received multiple inbound requests regarding the cardiovascular product line.
Ferguson said potential strategic transactions involving SimpliDerm and the cardiovascular business would further bolster the balance sheet. He said Elutia believes its current capital position provides the resources needed to support planned regulatory and operational milestones.
About Elutia (NASDAQ:ELUT)
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small?molecule donors.
The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
